Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2024.107498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Zheng Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Xinjiang Key Laboratory of Natural Medicine Active Components and Drug Release Technology, College of Pharmacy, Xinjiang Medical University, Urum…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Uterine Cervical Neoplasms, Drug Resistance, Neoplasm, Drug Design. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Chemotherapy toxicity and tumor multidrug resistance remain the main reasons for clinical treatment failure in cervical cancer. In this study, 79 novel chalcone derivatives were designed and synthesized using the principle of active substructure splicing with the parent nucleus of licorice chalcone as the lead compound and VEGFR-2 and P-gp as the target of action and their potentials for anticervical cancer activity were preliminarily evaluated. The results showed that the IC50 values of candidate compound B20 against HeLa and HeLa/DDP cells were 3.66 ± 0.10 and 4.35 ± 0.21 μΜ, respectively, with a resistance index (RI) of 1.18, which was significantly higher than that of the positive drug cisplatin (IC50:13.60 ± 1.63, 100.03 ± 7.94 μΜ, RI:7.36). In addition, B20 showed significant inhibitory activity against VEGFR-2 kinase and P-gp-mediated rhodamine 123 efflux, as well as the ability to inhibit the phosphorylation of VEGFR-2 and downstream PI3K/AKT signaling pathway proteins, inducing apoptosis, blocking cells in the S-phase, and inhibiting invasive migration and tubule generation by HUVEC cells. Acceptable safety was demonstrated in acute toxicity tests when B20 was at 200 mg/kg. In the nude mouse HeLa/DDP cell xenograft tumor model, the inhibition rate of transplanted tumors was 39.2 % and 79.2 % when B20 was at 10 and 20 mg/kg, respectively. These results suggest that B20 is a potent VEGFR-2 and P-gp inhibitor with active potential for treating cisplatin-resistant cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Xinjiang Key Laboratory of Natural Medicine Active Components and Drug Release Technology, College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China.
- The Xinjiang Key Laboratory of Natural Medicine Active Components and Drug Release Technology, College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China. Electronic address: mourboul@xjmu.edu.cn.
- Department of Gynecological Radiation Therapy Ⅱ Ward, The 3rd Affiliated Teaching Hospital of Xinjiang Medical University (Affiliated Cancer Hospital), Urumqi, Xinjiang 830011, China.
Zitieren
APA
Yang, Z., Wang, Y., Ablise, M., Maimaiti, A., Mutalipu, Z., Yan, T., Liu, Z. Y., & Aihaiti, A. (2024). Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107498
Vancouver
Yang Z, Wang Y, Ablise M, Maimaiti A, Mutalipu Z, Yan T, et al. Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107498
BibTeX
@article{Yang2024,
author = {Yang, Zheng and Wang, Yu and Ablise, Mourboul and Maimaiti, Aikebaier and Mutalipu, Zuohelaguli and Yan, Tong and Liu, Zheng-Ye and Aihaiti, Aizitiaili},
title = {Design, synthesis, and ex vivo anti-drug resistant cervical cancer activity of novel molecularly targeted chalcone derivatives},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2024.107498}
}
EUVIMED